Show simple item record

dc.contributor.authorClarkson, S
dc.contributor.authorBowes, L
dc.contributor.authorCoulman, E
dc.contributor.authorBroome, MR
dc.contributor.authorCannings-John, R
dc.contributor.authorCharles, JM
dc.contributor.authorEdwards, RT
dc.contributor.authorFord, T
dc.contributor.authorHastings, RP
dc.contributor.authorHayes, R
dc.contributor.authorPatterson, P
dc.contributor.authorSegrott, J
dc.contributor.authorTownson, J
dc.contributor.authorWatkins, R
dc.contributor.authorBadger, J
dc.contributor.authorHutchings, J
dc.date.accessioned2023-01-25T14:41:48Z
dc.date.issued2022-03-29
dc.date.updated2023-01-25T11:50:06Z
dc.description.abstractBACKGROUND: Reducing bullying is a public health priority. KiVa, a school-based anti-bullying programme, is effective in reducing bullying in Finland and requires rigorous testing in other countries, including the UK. This trial aims to test the effectiveness and cost-effectiveness of KiVa in reducing child reported bullying in UK schools compared to usual practice. The trial is currently on-going. Recruitment commenced in October 2019, however due to COVID-19 pandemic and resulting school closures was re-started in October 2020. METHODS: Design: Two-arm pragmatic multicentre cluster randomised controlled trial with an embedded process and cost-effectiveness evaluation. PARTICIPANTS: 116 primary schools from four areas; North Wales, West Midlands, South East and South West England. Outcomes will be assessed at student level (ages 7-11 years; n = approximately 13,000 students). INTERVENTION: KiVa is a whole school programme with universal actions that places a strong emphasis on changing bystander behaviour alongside indicated actions that provide consistent strategies for dealing with incidents of bullying. KiVa will be implemented over one academic year. COMPARATOR: Usual practice. PRIMARY OUTCOME: Student-level bullying-victimisation assessed through self-report using the extensively used and validated Olweus Bully/Victim questionnaire at baseline and 12-month follow-up. SECONDARY OUTCOMES: student-level bullying-perpetration; student mental health and emotional well-being; student level of, and roles in, bullying; school related well-being; school attendance and academic attainment; and teachers' self-efficacy in dealing with bullying, mental well-being, and burnout. SAMPLE SIZE: 116 schools (58 per arm) with an assumed ICC of 0.02 will provide 90% power to identify a relative reduction of 22% with a 5% significance level. RANDOMISATION: recruited schools will be randomised on 1:1 basis stratified by Key-Stage 2 size and free school meal status. Process evaluation: assess implementation fidelity, identify influences on KiVa implementation, and examine intervention mechanisms. Economic evaluation: Self-reported victimisation, Child Health Utility 9D, Client Service Receipt Inventory, frequency of services used, and intervention costs. The health economic analysis will be conducted from a schools and societal perspective. DISCUSSION: This two-arm pragmatic multicentre cluster randomised controlled trial will evaluate the KiVa anti-bullying intervention to generate evidence of the effectiveness, cost-effectiveness and scalability of the programme in the UK. Our integrated process evaluation will assess implementation fidelity, identify influences on KiVa implementation across England and Wales and examine intervention mechanisms. The integrated health economic analysis will be conducted from a schools and societal perspective. Our trial will also provide evidence regarding the programme impact on inequalities by testing whether KiVa is effective across the socio-economic gradient. TRIAL REGISTRATION: Trials ISRCTN 12300853 Date assigned 11/02/2020.en_GB
dc.description.sponsorshipNational Institute for Health Research (NIHR)en_GB
dc.identifier.citationVol. 22, No. 1, article 608en_GB
dc.identifier.doihttps://doi.org/10.1186/s12889-022-12642-x
dc.identifier.grantnumber17–92-11en_GB
dc.identifier.urihttp://hdl.handle.net/10871/132334
dc.identifierORCID: 0000-0001-7525-322X (Hayes, Rachel)
dc.language.isoenen_GB
dc.publisherBMCen_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/35351054en_GB
dc.rights© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the dataen_GB
dc.subjectBullyingen_GB
dc.subjectChildrenen_GB
dc.subjectCluster randomised controlled trialen_GB
dc.subjectCost-effectivenessen_GB
dc.subjectEconomic evaluationen_GB
dc.subjectEffectivenessen_GB
dc.subjectInterventionen_GB
dc.subjectKiVaen_GB
dc.subjectProcess evaluationen_GB
dc.subjectSchoolen_GB
dc.subjectSchool interventionen_GB
dc.subjectViolence preventionen_GB
dc.titleThe UK stand together trial: protocol for a multicentre cluster randomised controlled trial to evaluate the effectiveness and cost-effectiveness of KiVa to reduce bullying in primary schoolsen_GB
dc.typeArticleen_GB
dc.date.available2023-01-25T14:41:48Z
dc.identifier.issn1471-2458
exeter.article-number608
exeter.place-of-publicationEngland
dc.descriptionThis is the final version. Available on open access from BMC via the DOI in this record. en_GB
dc.identifier.journalBMC Public Healthen_GB
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_GB
dcterms.dateAccepted2022-01-25
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2022-03-29
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2023-01-25T14:18:17Z
refterms.versionFCDVoR
refterms.dateFOA2023-01-25T14:41:51Z
refterms.panelCen_GB
refterms.dateFirstOnline2022-03-29


Files in this item

This item appears in the following Collection(s)

Show simple item record

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco
mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data
Except where otherwise noted, this item's licence is described as © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data